Elevated serum levels of interleukin-1β and interleukin-33 in patients with systemic sclerosis in Chinese population

Zhang, Y.-J.; Zhang, Q.; Yang, Guo-Jun; Tao, J.-H.; Wu, Guo-Cui; Huang, Xiaolei; Duan, Yu; Li, X.-P.; Ye, D.-Q.; Wang, J.

doi:10.1007/s00393-016-0202-3

Cited by 20 publications

(20 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our finding of higher levels of serum IL‐18 in SSc patients than in HC is in line with a previously published study . We report, for the first time, negative correlations between serum IL‐18 and both KCO and DLCO.…”

Section: Discussionsupporting

confidence: 93%

“…The IL‐1 superfamily members IL‐1α, IL‐1β and IL‐18 are acknowledged to play a role in the pathogenesis of fibrosis and autoimmune disease, including SSc . Most SSc studies, however, have been conducted in small and poorly described populations . To date, our study is the largest and most ethnically diverse to investigate the clinical relevance of serum IL‐1α, IL‐1β and IL‐18 in SSc.…”

Section: Discussionmentioning

confidence: 99%

“…7 Most SSc studies, however, have been conducted in small and poorly described populations. 16,20,25 To date, our study is the largest and most ethnically diverse to investigate the clinical relevance of serum IL-1a, IL-1b and IL-18 in SSc. We observed that SSc patients have significantly higher levels of IL-18, but not IL-1a or IL-1b, than in HC.…”

Section: Discussionmentioning

confidence: 99%

“…One previous study has looked at IL‐1α, IL‐1β and IL‐18 (as well as the IL‐1 family cytokine IL‐33) in a relatively modest‐sized Chinese cohort (56 patients and 56 HC) and found that only serum IL‐1β and IL‐33 were higher in SSc in multivariable analysis. No clinical associations with any of these cytokines were found . Here, we examined the clinical relevance of serum IL‐1α, IL‐1β and IL‐18 in a large, well‐characterised and prospectively followed SSc cohort.…”

Section: Introductionmentioning

confidence: 99%

“…No clinical associations with any of these cytokines were found. 25 Here, we examined the clinical relevance of serum IL-1a, IL-1b and IL-18 in a large, well-characterised and prospectively followed SSc cohort. We found that serum IL-18, but not IL-1a or IL-1b, was significantly higher in SSc patients than in HC.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Analysis of serum interleukin(IL)‐1α, IL‐1β and IL‐18 in patients with systemic sclerosis

et al. 2019

View full text Add to dashboard Cite

Objectives Systemic sclerosis ( SS c) is an autoimmune disease characterised by fibrosis, vascular dysfunction and immune dysregulation. The pathogenesis of SS c remains poorly understood, although studies have indicated a role for the innate immune response. Methods Here, we measured serum interleukin ( IL )‐1α, IL ‐1β and IL ‐18 levels in 105 SS c patients and 47 healthy controls ( HC ) and analysed them with respect to multiple clinical parameters. Results Serum IL ‐18 concentrations were significantly higher in SS c patients than in HC , while no significant differences in concentrations of IL ‐1α and IL ‐1β were observed between SS c and HC . In both SS c and HC serum, IL ‐1α and IL ‐1β were positively correlated, while in SS c, both cytokines negatively correlated with IL ‐18. Serum IL ‐18 was significantly negatively correlated with both carbon monoxide transfer coefficient ( KCO ) and diffusing capacity of the lungs for carbon monoxide ( DLCO ). Serum IL ‐1β was positively correlated with the modified Rodnan skin score ( mRSS ), particularly in patients with limited subtype. DLCO , KCO and tricuspid regurgitation ( TR ) velocity were significantly higher in patients with high serum IL ‐1β. Serum IL ‐1α was significantly lower in SS c patients with low KCO and positively correlated with KCO . SS c patients with high serum IL ‐1α concentrations were more likely to have digital ulcers. Conclusions Our data suggest that these IL ‐1 family cytokines may have different roles in the pathogenesis of SS c fibrotic complications.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Analysis of serum interleukin(IL)‐1α, IL‐1β and IL‐18 in patients with systemic sclerosis

et al. 2019

View full text Add to dashboard Cite

show abstract

Serum Biomarkers Related to Glucocorticoid‐Induced Osteonecrosis of the Femoral Head: A Prospective Nested Case‐Control Study

Wang

Hua

Chang

et al. 2019

Journal Orthopaedic Research

View full text Add to dashboard Cite

Early diagnosis and prevention of glucocorticoid (GC)‐induced osteonecrosis of the femoral head (ONFH) continues to be a challenging problem for clinicians and researchers. However, the role of circulating biomarkers for GC‐induced ONFH, which may reveal individual susceptibility and facilitate earlier diagnosis, remains to be determined. The aim of this study was to identify potential biomarkers that may predict early GC‐induced ONFH. A total of 123 patients scheduled for initial systemic GC therapy were enrolled in this prospective nested case–control study. The serum concentrations of 13 potential biomarkers were measured in seven patients with GC‐induced ONFH, diagnosed instantly after short‐term use of GCs and in 20 controls who did not develop osteonecrosis despite similar GC therapy. Biomarkers were measured both before and after taking GCs to identify any differences in marker levels and the changes during GC therapy between two groups. Type I collagen cross‐linked C‐telopeptide (β‐CTX; p = 0.000) was significantly lower, high‐density lipoprotein cholesterol (p = 0.092) and apolipoprotein (apo)‐B/apo‐A1 (p = 0.085) tended to be lower and higher, respectively, before GC treatment in osteonecrosis group. After GC therapy, β‐CTX (p = 0.014) was significantly lower and amino terminal telopeptide of procollagen type I (PINP; p = 0.068) tended to be lower in the osteonecrosis group. As secondary outcomes, we observed remarkable changes in nine potential biomarkers following short‐term GC therapy in both groups. In conclusion, we found that β‐CTX, could potentially be used to predict GC‐induced ONFH before GC therapy. Lower β‐CTX and PINP are promising biomarkers for the early diagnosis of GC‐induced ONFH. These findings need to be confirmed in large‐scale prospective studies. © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 37:2348–2357, 2019

show abstract

Current Concepts on the Pathogenesis of Systemic Sclerosis

Truchetet

Brembilla²,

Chizzolini³

2021

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

From the clinical standpoint, systemic sclerosis (SSc) is characterized by skin and internal organ fibrosis, diffuse fibroproliferative vascular modifications, and autoimmunity. Clinical presentation and course are highly heterogenous and life expectancy variably affected mostly dependent on lung and heart involvement. SSc touches more women than men with differences in disease severity and environmental exposure. Pathogenetic events originate from altered homeostasis favored by genetic predisposition, environmental cues and a variety of endogenous and exogenous triggers. Epigenetic modifications modulate SSc pathogenesis which strikingly associate profound immune-inflammatory dysregulation, abnormal endothelial cell behavior, and cell trans-differentiation into myofibroblasts. SSc myofibroblasts show enhanced survival and enhanced extracellular matrix deposition presenting altered structure and altered physicochemical properties. Additional cell types of likely pathogenic importance are pericytes, platelets, and keratinocytes in conjunction with their relationship with vessel wall cells and fibroblasts. In SSc, the profibrotic milieu is favored by cell signaling initiated in the one hand by transforming growth factor-beta and related cytokines and in the other hand by innate and adaptive type 2 immune responses. Radical oxygen species and invariant receptors sensing danger participate to altered cell behavior. Conventional and SSc-specific T cell subsets modulate both fibroblasts as well as endothelial cell dysfunction. Beside autoantibodies directed against ubiquitous antigens important for enhanced clinical classification, antigen-specific agonistic autoantibodies may have a pathogenic role. Recent studies based on single-cell RNAseq and multi-omics approaches are revealing unforeseen heterogeneity in SSc cell differentiation and functional states. Advances in system biology applied to the wealth of data generated by unbiased screening are allowing to subgroup patients based on distinct pathogenic mechanisms. Deciphering heterogeneity in pathogenic mechanisms will pave the way to highly needed personalized therapeutic approaches.

show abstract

Elevated serum levels of interleukin-1β and interleukin-33 in patients with systemic sclerosis in Chinese population

Abstract: IL-1β and IL-33 may contribute to the development of SSc. While there were no direct associations between these cytokines and disease manifestations, they still could be considered as serum markers of development of SSc. Further studies are required to validate this incipient data.

Cited by 20 publications

References 34 publications

Analysis of serum interleukin(IL)‐1α, IL‐1β and IL‐18 in patients with systemic sclerosis

Analysis of serum interleukin(IL)‐1α, IL‐1β and IL‐18 in patients with systemic sclerosis

Serum Biomarkers Related to Glucocorticoid‐Induced Osteonecrosis of the Femoral Head: A Prospective Nested Case‐Control Study

Current Concepts on the Pathogenesis of Systemic Sclerosis

Contact Info

Product

Resources

About